# 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

> **NCT06233903** · PHASE2 · WITHDRAWN · sponsor: **Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)**

## Conditions studied

- Neuroblastoma
- Pheochromocytoma
- Paraganglioma

## Interventions

- **DRUG:** 18F-mFBG

## Key facts

- **NCT ID:** NCT06233903
- **Lead sponsor:** Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01
- **Primary completion:** 2025-09
- **Final completion:** 2025-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Logistical considerations
- **Last updated:** 2025-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06233903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06233903, "18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06233903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*